PRC-063 85 mg

DRUG2 trials

Sponsors

Rhodes Pharmaceuticals, L.P.

Conditions

ADHDAttention Deficit Hyperactivity Disorder (ADHD)

Phase 3

PRC-063 in Adolescent ADHD

CompletedNCT02139111

Rhodes Pharmaceuticals, L.P.ADHD

Start: 2014-04-30End: 2015-05-31Updated: 2015-07-08

PRC-063 in an ADULT Workplace Environment

CompletedNCT02225639

Rhodes Pharmaceuticals, L.P.Attention Deficit Hyperactivity Disorder (ADHD)

Start: 2014-08-31End: 2015-05-31Updated: 2015-07-09

Related Papers

Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up

Journal of Child and Adolescent Psychopharmacology2021-10-298 citations

Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension

Journal of Child and Adolescent Psychopharmacology2021-10-1210 citations

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD

Journal of Attention Disorders2021-06-308 citations

Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.

2021-05-316 citations